Eva Van Caenegem

TL;DR: Wierckx et al. as mentioned in this paper described the effects and side effects of cross-sex hormone therapy in both transsexual men and women, and found that none of the transsexual women experienced a hormone-related cancer during treatment, while a substantial number of women suffered from osteoporosis at the lumbar spine and distal arm.

TL;DR: The data reveal that the majority of transsexual men desire to have children, and more attention should be paid to this topic during the diagnostic phase of transition and to the consequences for genetic parenthood after starting sex reassignment therapy.

TL;DR: Wierckx et al. as discussed by the authors provided data on quality of life and sexual health after sex reassignment surgery (SRS) in transsexual men and found that most participants reported an increase in frequency of masturbation, sexual arousal, and ability to achieve orgasm after testosterone treatment and SRS.

TL;DR: Current treatment modalities were effective and carried a low risk for side effects and adverse events at short-time follow-up, and side effects, adverse events, and desired clinical changes were examined.

TL;DR: Wierckx et al. as mentioned in this paper reported the short-term effects of cross-sex hormone therapy on hormonal and clinical changes, side effects, and adverse events in trans men (female-to-male gender dysphoric persons) and trans women (maleto-female gender dysphoria persons) in a multicenter 1-year prospective study in 53 trans men and 53 trans women.